✦ LIBER ✦

Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma

✍ Scribed by Amir A. Toor; John Ayers; Joan Strupeck; Mala Parthasarathy; Steve Creech; Tulio Rodriguez; Patrick J. Stiff

Book ID: 108672526
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 211 KB
Volume: 124
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2004.04837.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mikulicz’s disease with severe thrombocy

Mikulicz’s disease with severe thrombocytopenia following autologous stem cell transplantation in a multiple myeloma patient

✍ Chihiro Sakurai; Kazuteru Ohashi; Kyogo Sakaguchi; Tsunekazu Hishima; Noriko Kam 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 412 KB

Cardiac toxicity of high-dose cyclophosp

Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation

✍ Samo Zver; Vesna Zadnik; Peter Černelč; Mirta Koželj 📂 Article 📅 2008 🏛 Carden Jennings Publishing 🌐 English ⚖ 298 KB

High-dose idarubicin, cyclophosphamide a

High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study

✍ R. Fenk; P. Schneider; M. Kropff; A. N. Huenerlituerkoglu; U. Steidl; C. Aul; B. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

Autologous stem cell transplantation in

Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis

✍ Shaji K. Kumar; David Dingli; Martha Q. Lacy; Angela Dispenzieri; Suzanne R. Hay 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

## Abstract High‐dose therapy and autologous stem cell transplant (HDT) have been shown to prolong survival in multiple myeloma (MM) in randomized trials, but only included patients of 65 years or younger. Given the median age at diagnosis of 66 years, it is important to have a better understanding

High-dose melphalan versus busulfan, cyc

High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma

✍ Don M. Benson Jr.; Patrick J. Elder; Thomas S. Lin; William Blum; Sam Penza; Bel 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 192 KB

Secondary primary malignancies in patien

Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation

✍ Roland Fenk; Florian Neubauer; Ingmar Bruns; Thomas Schröder; Ulrich Germing; Ra 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB